Sagimet Biosciences Inc. - Seri
SGMT
Positions held
Your positionsSGMT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $632.51M | Enterprise value | $316.27M | Trailing P/E | — | Forward P/E | -6.86 |
| PEG | — | Price / book | 2.15 | Beta | 3.49 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -24.4% | ROA | -16.4% | Debt / equity | 0.01 |
| Current ratio | 45.03 | Free cash flow | -$27.82M | Analyst recommendation | strong_buy | Mean target | $27.91 |
| 52w high | $11.45 | 52w low | $4.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$14.0M | -$10.7M | -$9.6M | -$12.9M | -$10.4M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$15.8M | -$11.7M | -$10.8M | -$14.3M | -$11.9M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $2.0M | $0.0M | — |
| Op margin | — | — | -1537.0% | — | — |
| Net income | -$51.0M | -$45.6M | -$27.9M | -$30.5M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$56.9M | -$54.5M | -$30.7M | -$31.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-04 · Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
2026-10-01 · Sagimet Biosciences Closes Offering of Shares, Warrants
2026-10-01 · Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
2026-10-01 · Sagimet Biosciences Phase 3 Trial of Denifanstat as Acne Treatment Has High Success Probability, Wedbush Says
2026-10-01 · Oppenheimer Adjusts Price Target on Sagimet Biosciences to $38 From $33, Maintains Outperform Rating
2026-09-30 · Sector Update: Healthcare Stocks Softer Wednesday Afternoon
2026-09-30 · Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data
2026-09-30 · Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday
2026-09-30 · Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market
2026-09-30 · Sagimet Biosciences' Denifanstat Shows Sustained Improvements in 52-Week Acne Trial
2026-09-30 · Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell
Price (daily)
Full chart · RSI · MACD · patterns